Logo of openbiojLink to Publisher's site
Open Biochem J. 2012; 6: 31–39.
Published online Apr 19, 2012. doi:  10.2174/1874091X01206010031
PMCID: PMC3339428

Effects of Nerve Growth Factor and Nitric Oxide Synthase Inhibitors on Amyloid Precursor Protein mRNA Levels and Protein Stability

Abstract

We determined previously that nitric oxide (NO) modulates the nerve growth factor (NGF)-mediated increases in amyloid precursor protein (APP) levels in PC12 cells. To elucidate potential mechanisms, the effects of NGF and NO synthase (NOS) inhibitors on APP mRNA levels and protein stability were evaluated. Surprisingly, treatment of PC12 cells with NGF resulted in decreased levels of APP695 and APP751/770 mRNA. Therefore, the effect of NGF on APP protein stability was examined using the translation inhibitor, cycloheximide. Under these conditions, NGF did not alter the rate of APP degradation, suggesting that NGF may be enhancing the translation rate of APP. Since NOS inhibitors attenuate the NGF-mediated increase in APP levels, their effect on APP mRNA levels and protein stability was also assessed. S-methylisothiourea (S-MIU), selective for inducible NOS, decreased both APP695 and APP751/770 mRNA levels while the non-selective NOS inhibitor, Nω-nitro-L-arginine methylester (L-NAME) had no effect. In both control and NGF-treated PC12 cells, S-MIU increased the half-life of APP, with the greatest effect observed with the APP695 isoform. Based on these data we propose that in PC12 cells, NGF increases APP levels through enhanced translation rate and that NO, which modulates the NGF-induced increase in APP protein, also regulates APP mRNA levels and could play a role in APP processing.

Keywords: Amyloid precursor protein, mRNA, nerve growth factor, nitric oxide, PC12 cells, protein stability.

INTRODUCTION

Currently, elevated levels of amyloid β-protein (Aβ) are most often implicated in the progression of Alzheimer’s disease (AD; reviewed in [1]). Aβ is produced during the normal cleavage of the glycoprotein amyloid precursor protein (APP), which is expressed in the membrane of neurons and glial cells [2]. Alternative splicing of the APP gene results in the generation of several isoforms, ranging in size from 365 to 770 amino acids, with APP695 being the most abundantly expressed isoform in the brain [3-5]. While many studies have focused on APP metabolism and the production of Aβ, the mechanisms involved in regulating APP isoform expression have not been elucidated.

Nerve growth factor (NGF), a neurotrophin reported to benefit AD patients [6], has also been found to modulate the levels and post-translational processing of APP. Several studies, using PC12 cells or primary neurons have reported that NGF increases APP mRNA and protein levels [7 - 10]. In PC12 cells, this is primarily the result of an up-regulation of the APP695 isoform [7, 10]. The levels of all three isoforms of nitric oxide synthase (NOS) are also increased following treatment with NGF [11, 12] and we found that NOS inhibitors attenuate the increase in APP protein levels caused by NGF [7]. Interestingly, we also found that this inhibition of NOS only partially attenuated the increase in APP promoter activation mediated by NGF [7] suggesting that NGF- signal transduction pathways and NO may be influencing the rate of APP mRNA or protein synthesis or degradation in addition to altering gene transcription. Therefore, in the present study we investigated the effects of NGF and NOS inhibitors, alone and in combination, on APP mRNA levels and protein stability in PC12 cells. We determined previously that the non-selective inhibitor, Nω-nitro-L-arginine methylester (L-NAME) and s-methylisothiourea (S-MIU), selective for the inducible NOS isoform [13], inhibited NOS activity in PC12 cells [11] and modulated NGF-induced APP expression [7]. Therefore these inhibitors were used to examine the role of NO on steady-state APP mRNA and protein levels. APP protein stability was assessed in PC12 cells exposed to NGF and/or NOS inhibitors followed by treatment with the translation inhibitor cycloheximide.

MATERIALS AND METHODS

Materials

Dulbecco's modified Eagle medium (DMEM), horse serum, gentamycin, Trizol and reverse transcription reagents were supplied by Invitrogen (Carlsbad, CA) and fetal bovine serum was purchased from HyClone Laboratories (Logan, UT). Harlan Bioproducts for Science (Indianapolis IN) was the supplier for NGF and Sigma Aldrich (St. Louis, MO) the source for L-NAME, S-MIU, actinomycin D, cycloheximide and the mouse monoclonal α-tubulin antibody. The complete mini tablets were obtained from Roche Diagnostics (Laval, QC), the protein standards and sodium dodecyl sulfate (SDS) sample buffer were purchased from New England Biolabs (Ipswich, MA) and the SYBR green polymerase chain reaction reagents were from Qiagen (Mississauga, ON). Mouse monoclonal anti-APP was purchased from Chemicon International (Temecula, CA) and Amersham/GE Health Care (Piscataway, N.J.) supplied the Hybond blotting membrane, sheep anti-mouse IgG, Rediprime® random primer labelling system and the enhanced chemiluminescence (ECL) kit. All other chemicals were purchased either from Fisher Scientific (Ottawa, ON) or DiaMed Laboratories (Mississauga, ON) and were electrophoresis or molecular grade.

PC12 Cell Culture

PC12 cells were maintained, plated and treated as described previously [7, 11]. Media consisted of DMEM supplemented with 5% fetal bovine serum, 5% horse serum and 50 μg/mL gentamycin and cells were plated onto Corning® CellBind® coated dishes at a density of 2.0 million cells per 100 mm dish for RNA analysis and at a density of 1.0 million cells per 60 mm dish for protein analysis, 24 h prior to experiments.

NGF and Inhibitor Treatments

To determine a temporal profile for the effects of NGF on APP levels, samples from untreated PC12 cells or cells treated with 50 ng/mL NGF were collected at 12 or 24 hour intervals for a maximum of 96 h. The cell culture media and NGF treatment was replaced every 48 hours. The role of NO on APP mRNA levels or protein stability was examined in PC12 cells treated with 20 mM L-NAME or 0.5 to 2.0 mM S-MIU alone or 1 h before treatment with NGF [7, 11]. The effect of NGF on APP mRNA half-life was assessed in PC12 cells treated for 24 h with NGF followed by treatment with 1 μg/mL actinomycin D for 1, 2, 4 or 8 h. The effect of NGF on APP protein translation was assessed in PC12 cells treated for 72 h with NGF or NOS inhibitors, alone or in combination, followed by treatment with 10 μg/mL cycloheximide for 0.25, 0.5, 1 or 2 h. For protein studies, media and treatments were replaced at the 48 h time-point, as described above.

Immunoblot Analysis

PC12 cell samples were obtained and analyzed as described previously [7]. Briefly, cells were lysed in 250 μL of radioimmunoprecipitation assay (RIPA) buffer, rocked on ice for 15 min, sonicated and centrifuged for 15 min at 17 530 g. Supernatant protein content was determined by the method of Bradford [14] and 35 μg of cell lysate was boiled in SDS sample buffer. Proteins were separated by 10% SDS/polyacrylamide gel electrophoresis and transferred onto Hybond-C nitrocellulose membranes using a Trans-blot semidry transfer unit (Bio-Rad Laboratories, Mississauga, ON). Membranes were blocked for 1 h in 5% non-fat milk in TRIS-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T). Membranes were incubated over night in 1:50,000 anti-α-tubulin or 1:500 anti-APP in 5% non-fat milk in TBS-T. Proteins were detected following a 1 h exposure to1:2000 horseradish peroxidase conjugated sheep anti-mouse IgG in 5% non-fat milk in TBS-T, ECL and subsequent scanning of the membranes with the STORM 860 (Molecular Dynamics, subsidiary of Amersham). Relative protein levels were and quantified densitometrically using Imagequant software (Molecular Dynamics).

Quantitative RT- PCR

Total RNA was isolated from PC12 cells using Trizol. Extracted RNA (5 μg) was reverse transcribed with Superscript II, using oligo-dt as the primer, for 75 min at 43°C and the cDNA generated was used for real-time PCR. All PCR reactions were performed in a LightCycler (Roche Diagnostics) using SYBRgreen PCR reagents in a final volume of 10 μL. Each cycle began with an initial activation phase at 95°C for 15 min followed by 45 cycles of 15 s at 95oC, 20 s at 55oC and 15 s at 72oC. The primers used to amplify APP and the house keeping gene beta-2 microglobulin were: APP forward: 5’ cgt ttg tga gcc cca tct tc 3’, APP reverse: 5’ ttc ctc ctc ttc ggc tac ttc 3’, beta-2 microglobulin forward: 5’ tga ccg tga tct ttc tgg gtg 3’ and beta-2 microglobulin reverse: 5’ atc tga ggt ggg tgg aac ctg 3’.

Northern Blot Analysis

Total RNA was isolated from PC12 cells as described above. For each sample, 20 µg of RNA was subjected to electrophoresis in 0.8% formaldehyde/agarose gels and transferred to nylon membranes (Hybond N) using a semi-dry transfer apparatus (Bio-Rad Laboratories). Membranes were UV-cross-linked and prehybridized at 42 °C for 1 h in 6 × SSPE (saline/sodium phosphate/EDTA), 0.5% SDS, 5 × Denhardts' reagent, 20 µg/mL salmon sperm DNA, and 50% formamide. Probes were generated for rat APP695 and APP751/770 by PCR using the following primers: APP695 forward: 5’ tga aaa gct tgt agt ccg agt tcc cac gac 3’ , APP695 reverse: 5’ tgt tac tag tct tcc tgt tcc aga gat tcc aac 3’, APP751/770 forward: 5’ act gaa gct ttc ttt tac ggc gga tgt g 3’ and APP751/770 reverse: 5’ aag aac tag tac ctc tct ttg gct ttc tgg 3’ A cDNA probe for murine 7S RNA [15] was used to normalize RNA loading. The probes were radiolabelled using 50 µCi of [α-32P]dCTP and the Rediprime® random primer labelling system and incubated with the membranes at 42 °C for 18 h in a solution identical to the prehybridization solution. Membranes were washed twice (15 min each) in 2 × SSC, 1% SDS at 42 °C and once (30 min) in 0.1× SSC, 0.1% SDS at 55 to 60 °C. For APP695 or APP751/770, the blots were left in phosphoimaging cassettes for 48 h, while the 7s blots were exposed for 30 min. The phosphoimaging screens were then scanned on the STORM 860 (Molecular Dynamics) for visualization and the bands analyzed densitometrically using Imagequant software (Molecular Dynamics).

Data Analysis and Statistics

Real-time PCR analysis was carried out using RelQuant software (Roche Diagnostics) and APP levels were quantified relative to beta-2 microglobulin levels in the same sample. For the analysis of both western and northern blots, bands for APP, α-tubulin (for protein) or 7s (for RNA) were analyzed densitometrically and levels expressed as a percentage of the total amount of each protein or mRNA level present on the entire blot [as in 7]. APP protein levels were then expressed relative to α-tubulin and APP RNA normalized to 7s levels within the same sample. At least 4 independent experiments were run for each data point and the data are presented as the mean ± standard error of the mean (SEM). All data were assessed for normality and homogeneity of variance and statistical analysis was carried out using a one-way analysis of variance (ANOVA). To determine significant differences between treatment groups, ANOVA was followed by either the Dunnett or Tukey-Kramer multiple comparisons test. Mean values were considered different if p<0.05.

RESULTS

Effect NGF on APP mRNA Levels

To assess the temporal effects of NGF on APP mRNA, PC12 cells were treated with 50 ng/mL NGF and the samples collected at 24 h intervals for a maximum of 96 h. Using primers that detected total APP mRNA (both APP695 and 751/770 isoforms), real-time PCR analysis revealed a decrease in the steady-state levels of APP mRNA (Fig. 1A1A). To confirm these findings and to determine whether this NGF-mediated decrease was isoform selective, PC12 cells were treated with 50 ng/mL of NGF, RNA harvested at 12 h intervals for 96 h and mRNA levels evaluated using probes generated to detect APP695 and APP751/770 specifically by northern blot analysis (Fig. 1B1B). Again, densitometric analysis revealed that steady-state mRNA levels of APP were reduced following NGF treatment, with significant decreases in APP695 mRNA detected from 36 to 96 h (Fig.1C1C; * p < 0.05) and a significant decrease in APP751/770 detected between 24 and 96 h (Fig. 1D1D; *p < 0.05; *** p < 0.001) of NGF treatment. The effect of NGF on APP mRNA half-life was examined in samples obtained from cells cultured with or without NGF for 24 h and treated with actinomycin D for 1, 2, 4 and 8 h. Since the effect of NGF was not isoform specific, APP mRNA levels were assessed using real-time PCR with primers that detected total APP (Fig. 1E1E). The level of APP mRNA was lower in cells treated with NGF relative to control in the absence of actinomycin D and following treatment with actinomycin D for 1 and 2 h (*p< 0.05). Although the estimated APP mRNA half-life was shorter in NGF treated cells (2.1 h) compared to control (2.8 h) this difference was not statistically significant.

Fig. (1)
Analysis of steady-state APP mRNA expression. (A) Real-time PCR analysis of total APP mRNA relative to beta-2 microglobulin levels following treatment with 50 ng/mL NGF. (B) Representative northern blots of APP695 (upper panel), APP751/770 (middle panel) ...

Effect of Cycloheximide D on APP Protein Levels

To examine whether NGF influences APP protein stability, cells were cultured in the presence or absence of NGF for 72 h and treated with cycloheximide from 15 min to 2 h. Representative western blots depicting APP and α-tubulin levels under these treatment conditions are presented in Fig. (2A2A). We determined previously that the highest protein band in the upper panel of Fig. (2A2A) shows mature APP751/770 and the immature APP695 isoform is depicted in the lowest band [7]. The middle band in this upper panel, which can sometimes be seen as 2 distinct bands, contains both immature APP751/770, and mature APP695. Relative expression of α-tubulin levels from the same samples is shown in the bottom panel of Fig. (2A2A). Following densitometric analysis, protein levels of the highest molecular weight APP isoform (Fig. 2B2B) and the lower band (Fig. 2D2D) that contained the immature APP695 isoform were significantly higher than control (*P<0.05) prior to the addition of cycloheximide but no difference in the levels or rate of decay of APP was observed at any of the time points following treatment with cycloheximide. The levels of immature APP751/770 and mature APP695 (Fig. 2C2C) was not different following 72 h of NGF treatment in the presence or absence of cycloheximide at any of the time points examined.

Fig. (2)
APP protein levels in control and NGF-treated PC12 cells in the presence or absence of cycloheximide. (A) Representative immunoblots obtained from lysates of control (untreated) and NGF (50 ng/mL) treated PC12 cells treated with 10 µg/mL cycoheximide ...

Effect of L-NAME or S-MIU on APP mRNA Levels and Protein Stability

Northern blot analysis was used to evaluate the effects of NOS inhibitors on APP mRNA levels. Densitometric analysis of mRNA levels for APP695 and APP751/770 normalized to 7s following treatment with NGF and NOS inhibitors are depicted in Fig. (33). For both APP695 (Fig. 3A3A) and APP751/770 (Fig. 3B3B) there was a significant decrease in steady-state mRNA levels following treatment with 1.5 and 2.0 mM S-MIU in comparison to control levels (*** p < 0.001). NGF also decreased the level of both transcripts but the levels of APP695 and APP751/770 mRNA were not different in samples obtained from NGF treated cells cultured with or without S-MIU. In contrast, treatment with L-NAME did not alter APP mRNA levels in either the presence or absence of NGF.

Fig. (3)
Northern blot analysis of steady-state APP and 7s mRNA levels after treatment with increasing concentrations of S-MIU and 20mM L-NAME in the presence or absence of NGF. (A) APP695 mRNA levels: NGF (50 ng/mL) alone and 1.5 or 2.0 mM S-MIU with and without ...

To determine whether NOS inhibition affected APP protein stability, control (untreated) and NGF-treated cells were grown in the presence or absence of 2.0 mM S-MIU and treated with cycloheximide from 15 min to 2 h. Densitometric analysis of APP isoform protein levels are presented in Fig. (44). There was no difference in the level of the highest molecular weight APP isoform in samples obtained from control or S-MIU-treated cells but a statistically significant difference between the levels of this isoform in control and S-MIU treated cells following treatment with cycloheximide for 60 and 120 min was observed (*p<0.05; Fig. 4A4A). The levels of immature APP751/770 isoform and mature APP695, which were quantified together (Fig. 4B4B) and immature APP695 isoform (Fig. 4C4C) were significantly lower in cells treated with S-MIU as compared to control (**p<0.01). In the presence of cycloheximide, the level of these APP isoforms declined steadily, while in the presence of S-MIU and cycloheximide, the levels of APP protein remained constant resulting in significantly lower levels of the smaller isoforms of APP in control cells as compared to those treated with S-MIU following treatment with cycloheximide for 60 and 120 min (*p<0.05; **p<0.01). In the presence of NGF, there was no difference in the levels or the rate of decay of mature APP751/770 in cells cultured with or without S-MIU (Fig. 4D4D). In cells treated with NGF and S-MIU, the relative level of the middle APP band, containing immature APP751/770 and mature APP695 (Fig. 4E4E) was significantly lower in NGF-treated cells pretreated with S-MIU prior to cycloheximide treatment (*p<0.05) and significantly higher following 2 h of exposure to cycloheximide (*p<0.05) when compared to cells treated with NGF alone. Densitometric analysis of the band containing the immature APP695 isoform (Fig. 4F4F) revealed a significantly lower level of this APP isoform in cells treated with NGF and S-MIU as compared to those treated with NGF alone (**p<0.01). In the presence of cycloheximide, immature APP695 levels in cell extracts of NGF-treated cells declined steadily over time, while in cells receiving both NGF and S-MIU, the level of this APP isoform remained constant resulting in significantly higher levels of immature APP695 in cells that received NGF and S-MIU compared to those exposed to NGF alone at the 120 min cycloheximide treatment time point (**p<0.01).

Fig. (4)
APP protein levels following cycloheximide treatment in control and NGF-treated PC12 cells grown in the presence or absence of S-MIU. Densitometric analysis of mature (m) APP751/770 (A) immature (i) APP751/770 and mAPP695 (B) and iAPP695 (C) protein expression ...

DISCUSSION

In PC12 cells, NGF treatment induces neurite outgrowth and increases the levels of APP protein [7, 10, 16 - 18], and we reported previously that NO modulates both of these actions of NGF [7]. To assess the mechanisms through which NO regulates these actions, we examined the effects of NGF, L-NAME and S-MIU on APP mRNA levels and protein stability. While NGF did increase APP protein levels, steady-state APP mRNA levels were decreased in NGF-treated PC12 cells. Although the estimated half-life of APP mRNA was lower in NGF-treated cells compared to control, this difference was not statistically significant. It was also demonstrated that the administration of NGF did not alter the stability of APP protein. These data suggest that, NGF may elevate APP levels in part through enhanced translation. A similar decrease in APP mRNA levels was observed in PC12 cells grown in the presence of the iNOS selective inhibitor, S-MIU. In contrast, L-NAME, the non-selective inhibitor, did not alter APP mRNA levels and neither inhibitor affected the ability of NGF to lower APP mRNA expression. In addition, treatment of PC12 cells with S-MIU resulted in a decrease in the level of APP protein, but an increase in APP half-life, primarily affecting the APP695 isoform. When NO production was inhibited, the basal levels of APP mRNA and protein were reduced and the increase in APP protein expression normally observed following NGF treatment was prevented. However, in both control and NGF-treated cells, the protein half-life of APP was prolonged in the presence of S-MIU, indicating NO plays a dual role in regulating APP levels.

Several APP isoforms can be produced from the APP gene however; APP695, APP751, and APP770 predominate in most mammalian tissues (reviewed in [19]). These isoforms can exist in both immature and mature forms, with mature forms being N- and O-glycosylated and tyrosyl sulfated as a result of post-translational processing [20]. APP695 is highly expressed in neurons [21] and it is the mature form of this isoform that is phosphorylated during PC12 cell differentiation [16]. Our finding that NO plays a dual role in modulating the levels of the APP695 isoform could be important with respect to understanding the regulation of neuronal APP expression and the role of both NO and APP in neuron function and in regulating the outgrowth of neurites.

We and others have reported that NGF enhances the expression of both APP [7 - 10, 22 -25] and NOS [11, 12, 26] and both NO [11, 12] and APP [16 - 18] have been identified as important contributors to neurite extension. While the interplay between NO and APP has not been fully elucidated, several studies have highlighted links between APP and NO. The c-terminal fragment of APP was reported to increase iNOS expression and NO production [27, 28] and both APP and constitutive NOS were found to be elevated in a subset of neurons following injury [29]. We reported previously that treatment with NOS inhibitors attenuated NGF-stimulated APP promoter activation and the increase in protein levels [7]. To further characterize the link between NO and APP, the actions of NGF and NOS inhibitors on APP mRNA levels and APP protein stability were evaluated.

Previous studies reported that NGF induction of APP mRNA involves activation of the Ras-MAPK signalling pathway [22, 25]. We and others have shown that NO modulates the MAPK signalling pathway [30, 31] suggesting NO could also play a role in the regulation of APP mRNA expression. In contrast to previous reports, using both real-time PCR and northern blot analysis, we found that treatment of PC12 cells with NGF decreased steady-state APP mRNA levels. It is possible that different cell types or lines of PC12 cells exhibit different gene expression profiles. The PC12 cells used in the present study were from American Type Culture Collection (ATCC, Rockville, MD, USA) while other studies investigating APP mRNA levels used primary neurons [9] or PC12 cells supplied by Dr. L. Greene [10]. The decrease in APP mRNA levels observed in the present study was not isoform specific as the steady-state mRNA levels of both APP695 and APP751/770 were below control values following treatment with NGF. The observed decrease in APP mRNA levels was surprising as it did not correlate our previous NGF-induced transcription and protein expression findings [7]. Using the same cell line and treatment conditions, we reported previously that APP promoter activity was increased following treatment with NGF and that the NGF-induced increase in APP protein levels was attenuated by pre-treatment with the transcription inhibitor actinomycin D [7].Our initial findings agreed with previous reports [8-10] and indicated that the NGF-mediated increase in APP protein levels was due to increased APP transcription however, the data in the present study suggest that this enhanced transcription does not result in increased APP mRNA levels. Taken together, these findings suggest the enhanced transcription of APP induced by NGF is followed by rapid translation and degradation of APP mRNA. This rapid degradation of APP mRNA is supported by the lower estimated half-life observed in NGF-treated PC12 cells relative to control, however this difference was not statistically significant at the NGF treatment timepoint examined. Interestingly the iNOS selective inhibitor S-MIU also reduced APP mRNA expression and like NGF, the effect of S-MIU on APP mRNA levels was not isoform specific. We reported previously that S-MIU did not affect basal APP promoter activity [7] suggesting that this reduction in APP mRNA levels is also due to an alteration in mRNA stability and not the result of inhibiting APP transcription. Furthermore, while the levels of both APP695 and APP751/770 mRNA were reduced significantly in samples obtained from cells receiving both NGF and S-MIU relative to untreated (control) cells, these levels were not different from those measured in extracts obtained from cells receiving either of these treatments alone. This indicates that the effects of NGF and NOS inhibition on steady-state APP mRNA levels are not additive and could involve similar mechanisms. The finding in this study that APP mRNA expression is decreased in PC12 cells treated with NGF or NOS inhibitors is unique and requires further investigation.

To better understand how NGF and NO were affecting APP protein turnover, the effect of cycloheximide on untreated PC12 cells and cells treated with NGF or S-MIU alone and in combination was evaluated. We reported previously that the level of the APP695 isoform was increased significantly following 96 h of treatment with NGF. To determine whether this increase is due in part to alterations in protein stability, cycloheximide was added to PC12 cells 72 h after NGF treatment was initiated, the time at which the trend towards increased APP levels was first observed [7]. In the present study no change in the half-life of any of the APP isoforms was observed following exposure to NGF. Since NGF did not increase the levels of APP mRNA or protein stability, our findings suggest that in PC12 cells NGF increases APP protein expression through enhanced transcription, followed by rapid translation and degradation of APP mRNA. In contrast to NGF, the iNOS-selective inhibitor S-MIU decreased the relative levels of APP protein in both the presence and absence of NGF but the degradation of APP was inhibited. These findings suggest that in addition to its role in regulating APP transcription NO could modulate mRNA stability as well as APP processing. NO was reported to increase the activity of tumor necrosis factor α-converting enzyme (TACE) [32] and under conditions of ischemia, activation of NOS was found to increase beta-site APP cleavage enzyme 1 (BACE-1) expression [33]. If in our system NO causes a similar increase the activity or expression of TACE, BACE-1 or one of the other α-secretase candidates, this could affect the level of full-length APP protein detected. Similarly, inhibition of NOS could prevent the degradation of APP by secretases, resulting in the prolonged half-life of this protein. In the present study, treatment of PC12 cells with S-MIU resulted in a reduction in the relative levels of APP protein and enhanced the protein stability and these effects were most consistently observed for the APP695 isform. We therefore speculate that NO does indeed modulate both the expression and cleavage of neuronal APP. Future studies are necessary in order to explore this relatively uncharacterized role of NO.

Since APP plays an important role in neuron function and its cleavage products are involved in the pathogenesis of AD, a better understanding of the mechanisms involved in regulating APP expression and its post-translational processing are necessary. The present study demonstrates that the NGF-mediated increase in APP protein levels is not due to enhanced mRNA or protein stability and that NO, which is necessary for NGF-induced neurite outgrowth and increased APP protein levels in PC12 cells, modulates APP mRNA levels and protein stability. NO plays an important role in the regulation of APP expression and the neurotrophic actions of NGF. Additional studies on the mechanisms involved in these complex processes would provide valuable insight into the neuromodulatory actions of both NO and APP.

ACKNOWLEDGEMENTS

This research was funded by a discovery grant from the Natural Sciences and Engineering Research Council of Canada.

ABBREVIATIONS

AD
 = Alzheimer’s disease
 = Amyloid β-protein
ANOVA
 = Analysis of variance
APP
 = Amyloid precursor protein
BACE-1
 = Beta-site APP cleavage enzyme 1
DMEM
 = Dulbecco’s modified Eagle medium
ECL
 = Enhanced chemiluminescence
L-NAME
 = Nω-nitro-L-arginine methyl ester
NGF
 = Nerve growth factor
NO
 = Nitric oxide
NOS
 = Nitric oxide synthase
PBS
 = Phosphate buffered saline
RIPA
 = Radioimmunoprecipitation assay
SDS
 = Sodium dodecyl sulfate
SEM
 = Standard error of the mean
S-MIU
 = S-methylisothiourea
TACE
 = Tumor necrosis factor α-converting enzyme
TBS
 = TRIS buffered saline
TBS-T
 = TBS containing 0.1 % tween 20.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J. Neurochem. 2007;101:1172–1184. [PubMed]
2. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Ann. Rev. Neurosci. 1994;17:489–517. [PubMed]
3. Neve RL, Finch EA, Dawes LR. Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron. 1988;1:669–677. [PubMed]
4. Tanaka S, Shiojiri S, Takahashi Y, Kitag.uchi N, Ito H, Kameyama M, Kimura J, Nakamura S, Ueda K. Tissue-specific expression of three types of beta-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer’s disease brain. Biochem. Biophys. Res. Commun. 1989;165:1406–1414. [PubMed]
5. Tanzi RE, McClatchey AI, Lampert ED, Villa-Komaroff L, Gusella JF, Neve RL. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature. 1988;331:528–530. [PubMed]
6. Seiger A, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herliltz A, Lilja A, Lundqvist H, Långström B, Meyerson B, Persson A, Viitanen M, Winblad B, Olson L. Intracranial infusion of purified nerve growth factor to an Alzheimer patient:the first attempt of a possible future treatment strategy. Behav. Brain. Res. 1993;57:255–261. [PubMed]
7. Binnington JC, Kalisch BE. Nitric oxide synthase inhibitors modulate nerve growth factor-mediated regulation of amyloid precursor protein expression in PC12 cells. J. Neurochem. 2007;101:422–433. [PubMed]
8. Fukuyama R, Chandrasekaran K, Rapoport SI. Nerve growth factor –induced neuronal differentiation is accompanied by differential induction and localization of the amyloid precursor protein (APP) in PC12-cells and variant PC12S-cells. Mol. Brain Res. 1993;17:17–22. [PubMed]
9. Ohyagi Y, Tabira T. Effects of growth factors and cytokines on expression of amyloid beta protein precursor messenger RNAs in culture neuronal cells. Mol. Brain Res. 1993;18:127–132. [PubMed]
10. Roßner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. p75 and TrkA receptor signaling independently regulate APP mRNA expression, isoform composition and protein secretion in PC-12 cells. J. Neurochem. 1998;71:757–564. [PubMed]
11. Kalisch BE, Bock NA, Davis W, Rylett RJ. Inhibitors of nitric oxide synthase attenuate nerve growth factor-mediated increases in choline acetyltransferase gene expression in PC12 cells. J. Neurochem. 2002;81:624–635. [PubMed]
12. Peunova N, Enikolopov G. Nitric oxide triggers a switch to growth arrest during differentiation of neuronal cells. Nature. 1995;375:68–73. [PubMed]
13. Southan GJ, Szabo C, Thiermermann C. Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br. J. Pharmacol. 1995;114:510–516. [PMC free article] [PubMed]
14. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–254. [PubMed]
15. Allan AL, Albanese C, Pestell RG, LaMarre J. Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J. Biol. Chem. 2001;276:27272–27280. [PubMed]
16. Ando M, Oishi M, Takeda S, Iijima K, Isohara T, Nairn AC, Kirino Y, Greengard P, Suzuki T. Role of phosphorylation of Alzheimer’s amyloid precursor protein during neuronal differentiation. J. Neurosci. 1999;19:4421–4427. [PubMed]
17. Luo J, Wallace MS, Hawver DB, Kusiak JW, Wallace WC. Characterization of the neurotrophic interaction between nerve growth factor and secreted α-amyloid precursor protein. J. Neurosci. Res. 2001;63:410–420. [PubMed]
18. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL. The amyloid protein precursor of Alzheimer’s disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron . 1992;9:129–137. [PubMed]
19. Jacobsen KT, Iverfeldt K. Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cell Mol. Life Sci. 2009;66:2299–2318. [PubMed]
20. Da Cruz e Silva EH, daCruz e Silva OA. Protein phosphorylation and APP metabolism. Neurochem. Res. 2003;28:1553–1561. [PubMed]
21. Kang J, Müller-Hill B. Differential splicing of Alzheimer’s disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain. Biochem. Biophys. Res. Commun. 1990;14:1192–1200. [PubMed]
22. Cosgaya JM, Latasa MJ, Pascual A. Nerve growth factor and ras regulate beta-amyloid precursor protein gene expression in PC12 cells. J. Neurochem. 1996;67:98–104. [PubMed]
23. Ge YW, Lahiri DK. Regulation of promoter activity of the APP gene by cytokines and growth factors:implications in Alzheimer’s disease. Ann NY Acad. Sci. 2002;973:463–467. [PubMed]
24. Higgins GA, Oyler GA, Neve RL, Chen KS, Gage F. Altered levels of amyloid protein precursor transcripts in the basal forebrain of behaviourally impaired aged rats. Proc. Natl. Acad. Sci. USA. 1990;87:3032–3036. [PMC free article] [PubMed]
25. Villa A, Latasa MJ, Pascual A. Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J. Neurochem. 2001;77:1077–1084. [PubMed]
26. Sheehy AM, Phung YT, Reimer RK, Black S. Growth factor induction of nitric oxide synthases in rat pheochromocytoma cells. Mol. Brain Res. 1997;52:71–77. [PubMed]
27. Bach JH, Chae HS, Rah JC, Lee MW, Park CH, Choi SH, Choi JK, Lee SH, Kim YS, Kim KY, Lee WB, Suh YH, Kim SS. C-terminal fragment of amyloid precursor protein induces astrocytosis. J. Neurochem. 2001;78:109–120. [PubMed]
28. Rah JC, Kim HS, Kim SS, Bach JH, Kim YS, Park CH, Seo JH, Jeong SJ, Suh YH. Effects of carboxyterminal fragment of Alzheimer’s amyloid precursor protein and amyloid beta-peptide on the production of cytokines and nitric oxide in glial cells. FASEB J. 2001;15:1463–1465. [PubMed]
29. Lüth H, Arendt T. Co-expression of APP with cNOS but not iNOS after cortical injury in rat. Neuroreport. 1997;8:2321–2324. [PubMed]
30. Kalisch BE, Demeris CS, Rylett RJ. Modulation of nerve growth factor-induced activation of MAP kinase in PC12 cells by inhibitors of nitric oxide synthase. J. Neurochem. 2003;87:1321–1332. [PubMed]
31. Kanterwicz BI, Knapp LT, Klann E. Stimulation of p42 and p44 mitogen-activated protein kinases by reactive oxygen species and nitric oxide in hippocampus. J. Neurochem. 1998;70:1000–1016. [PubMed]
32. Zhang A, Kols JK, Oliver P, Good D, Schwarzenberger PO, Hoshi MS, Ponthier JL, Lancaster JR., Jr Activation of tumor necrosis factor-α-converting enzyme-mediated ectodomain shedding by nitric oxide. J. Biol. Chem. 2000;275:15839–15844. [PubMed]
33. Li S, Wang W, Wang C, Tang YY. Possible involvement of NO/NOS signaling in hippocampal amyloid-beta production induced by transient focal cerebral ischemia in aged rats. Neurosci. Lett. 2010;470:106–110. [PubMed]

Articles from The Open Biochemistry Journal are provided here courtesy of Bentham Science Publishers
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...